Heparan sulfate binding cationic peptides restrict sars-cov-2 entry

Rahul K. Suryawanshi, Chandrashekhar D. Patil, Raghuram Koganti, Sudhanshu Kumar Singh, Joshua M. Ames, Deepak Shukla

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. While the world is striving for a treatment modality against SARS-CoV-2, our understanding about the virus entry mechanisms may help to design entry inhibitors, which may help to limit the virus spreading. Owing to the importance of cellular ACE2 and heparan sulfate in SARS-CoV-2 entry, we aimed to evaluate the efficacy of cationic G1 and G2 peptides in virus entry inhibition. In silico binding affinity studies revealed possible binding sites of G1 and G2 peptides on HS and ACE2, which are required for the spike–HS and spike–ACE2 interactions. Prophylactic treatment of G1 and G2 peptide was also proved to decrease the cell surface HS, an essential virus entry receptor. With these two mechanisms we confirm the possible use of cationic peptides to inhibit the entry of SARS-CoV-2.

Original languageEnglish
Article number803
Issue number7
StatePublished - 1 Jul 2021
Externally publishedYes


  • Cationic peptide
  • Entry inhibitors
  • Heparan sulfate
  • Pseudotyped virus
  • SARS-CoV-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Molecular Biology
  • Immunology and Microbiology (all)
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Heparan sulfate binding cationic peptides restrict sars-cov-2 entry'. Together they form a unique fingerprint.

Cite this